CRISPR Screen Dataset
Palit SA (2019) - 1-PMID31855178
Title: TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
Screen Details:
- Screen Rationale : Increased drug resistance
- Cell Type : Prostate Cancer Cell Line [BTO:0001033]
- Cell Line : LNCaP [BTO:0001321, CELLOSAURUS:CVCL_0395]
- Phenotype : Response To Chemicals
- Condition : Apalutamide (2.0 µM) [ChemSpider]
- Library : GECKO | Type: CRISPRn | Format: Pool | Enzyme: Cas9 | Methodology: Knockout
- Analysis Method : MaGeCK | Number of Hits: 1,098 | Full Dataset Size: 22,021
- Experimental Setup : Drug Exposure | Duration: 6 Weeks
- Significance : Authors have indicated that results with Score.2 (p-Value) < 0.05 are to be considered significant. These results are indicated by '' in the HIT column of the table below.
Notes:
- KO of hit genes resulted in increased resistance to the AR inhibitor apalutamide in LNCaP cells
Score Distribution
< 0.99995
> 0.0000000149